CD274 and neoplasm: To improve the therapeutic efficacy of PD-1/PD-L1 inhibitors, nanotechnology-based DDS have been gradually introduced to achieve tumor-targeting drug delivery to enhance the interruption of the PD-1 and PD-L1 combination (38).